Compare LEGN & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGN | ACHC |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | LEGN | ACHC |
|---|---|---|
| Price | $22.33 | $14.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $69.67 | $24.38 |
| AVG Volume (30 Days) | 2.6M | ★ 3.5M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.18 |
| Revenue | $909,045,000.00 | ★ $3,265,548,000.00 |
| Revenue This Year | $68.83 | $6.50 |
| Revenue Next Year | $51.27 | $4.38 |
| P/E Ratio | ★ N/A | $12.11 |
| Revenue Growth | ★ 74.75 | 4.58 |
| 52 Week Low | $22.28 | $12.63 |
| 52 Week High | $45.30 | $47.08 |
| Indicator | LEGN | ACHC |
|---|---|---|
| Relative Strength Index (RSI) | 21.96 | 34.23 |
| Support Level | $26.43 | $13.60 |
| Resistance Level | $28.97 | $15.55 |
| Average True Range (ATR) | 1.57 | 0.95 |
| MACD | -0.43 | 0.08 |
| Stochastic Oscillator | 0.91 | 31.52 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.